April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Predictors of Visual Acuity Outcome and Time to Lesion Reactivation When Using Anti-VEGF Drugs to Treat Wet AMD.
Author Affiliations & Notes
  • Geeta Menon
    Ophthalmology, Frimley Park Hosp Nhs Fdtn Trust, Camberley, Surrey, United Kingdom
  • Yit C Yang
    Ophthalmology, Wolverhampton Eye Infirmary, Wolverhampton, United Kingdom
    School of health and vision sciences, Aston University, Birmingham, United Kingdom
  • Jonathan M Gibson
    School of health and vision sciences, Aston University, Birmingham, United Kingdom
  • Barney Reeves
    School of Clinical sciences, University of Bristol, Bristol, United Kingdom
  • Faruque Ghanchi
    Ophthalmology, Bradford Teaching Hospital NHS Foundation Trust, Bradford, United Kingdom
  • Usha Chakravarthy
    Institute of Clinical Science, Queens University of Belfast, Belfast, United Kingdom
  • Footnotes
    Commercial Relationships Geeta Menon, Alcon (F), Alimera (R), Allergan (F), Allergan (R), Bayer (F), Bayer (R), Novartis (F), Novartis (R), Oraya (R); Yit Yang, Alimera (C), Alimera (F), Alimera (R), Bayer (F), Bayer (R), Novartis (F), Novartis (R); Jonathan Gibson, Alimera (R), Allergan (R), Bayer (R), Novartis (F), Novartis (R); Barney Reeves, Janssen-Cilag (F); Faruque Ghanchi, Allergan (F), Allergan (R), Bayer (F), Bayer (R), Novartis (F), Novartis (R); Usha Chakravarthy, Alcon (F), Allergan (R), Bausch and Lomb (R), Bayer (F), Bayer (R), Neovista (F), Neovista (R), Novartis (F), Novartis (R), Oraya (F), Oraya (R), Pfizer (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1310. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Geeta Menon, Yit C Yang, Jonathan M Gibson, Barney Reeves, Faruque Ghanchi, Usha Chakravarthy, ; Predictors of Visual Acuity Outcome and Time to Lesion Reactivation When Using Anti-VEGF Drugs to Treat Wet AMD.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1310.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Among 297 participants with wet AMD assigned to discontinuous anti-VEGF treatment using ranibizumab or bevacizumab in the IVAN trial, we sought to quantify associations between (1) lesion area and activity with baseline visual function, and lesion characteristics and visual function with (2) reading 68 ETDRS or more at the last visit, (3) time to lesion reactivation after initial 3 injections and (4) the need for 3 or fewer injections/year.

Methods: Wet AMD lesions at baseline line were classified as more (presence of haemorrhage or classic CNV) or less active and by quartile of lesion area. Predictors investigated (all available after initial 3 injections) were: lesion characteristics and ETDRS distance acuity, logMAR near visual acuity (NVA) and Pelli-Robson contrast sensitivity (CS) at baseline and 3 months. Data were analysed by multiple linear, logistic or Cox regression, using the likelihood ratio test to optimize model fit.

Results: More active (-9.4 letters, 95%CI -12.7 to -6.1, p<0.0001) and larger lesions (-1.6 letter per quartile, 95%CI -3.0 to -0.1, p=0.03) were independently associated with reading fewer ETDRS letters at baseline; similar associations were observed for NVA and CS. ETDRS letters read at baseline and 3 months independently predicted reading 68 ETDRS or more at the last visit (pseudo r2 = 0.34, p<0.0001). Median (95% CI 44% to 56%) time to lesion reactivation was 78 days. Larger lesion area (but not activity) and worst quartile of ETDRS letters at baseline predicted longer time to lesion reactivation (p<0.002). Lesion area and NVA at baseline were the best independent predictors of needing 3 or fewer injections/year but the model fitted poorly (pseudo r2 = 0.04, p=0.04) and neither association was linear.

Conclusions: Participants presenting with larger and more active lesions had worse baseline visual function. ETDRS letters read at baseline and 3 months, but not lesion characteristics, predicted good ETDRS outcome. The factors investigated were unable to predict the need for few injections.

Keywords: 412 age-related macular degeneration • 453 choroid: neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×